Side-by-side comparison of AI visibility scores, market position, and capabilities
NY digital health platform with owned pharmacy at $350M revenue in men's health, women's health, and GLP-1 weight management; $876M raised competing with Hims & Hers for DTC telehealth prescription delivery.
Ro is a New York-based digital health platform — backed with $876 million raised from General Catalyst, SignalFire, L Catterton, and others at a peak $7 billion valuation — providing telemedicine consultations, prescription management, and pharmacy-grade medication delivery for men's health (erectile dysfunction, hair loss under the Roman brand), women's health (fertility, menopause under the Rory brand), primary care (Ro Primary Care), and weight management (body program with GLP-1 medications). Founded in 2017 by Zachariah Reitano, Rob Schutz, and Saman Rahmanian, Ro generated approximately $350 million in revenue in 2024, serving over 2 million patients who have completed consultations through its platforms.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.